Chris Schott
Stock Analyst at JP Morgan
(4.06)
# 553
Out of 5,106 analysts
151
Total ratings
66.35%
Success rate
7.13%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $28 → $35 | $31.54 | +10.97% | 20 | Dec 16, 2025 | |
| PRGO Perrigo Company | Maintains: Neutral | $20 → $18 | $13.68 | +31.58% | 14 | Dec 15, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,050 → $1,150 | $1,071.64 | +7.31% | 23 | Nov 18, 2025 | |
| OGN Organon & Co. | Maintains: Underweight | $14 → $12 | $7.09 | +69.25% | 3 | Nov 11, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $230 → $200 | $123.54 | +61.89% | 3 | Nov 5, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $675 → $775 | $682.31 | +13.58% | 9 | Nov 4, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $250 → $260 | $228.79 | +13.64% | 4 | Nov 3, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $145 → $150 | $125.19 | +19.82% | 8 | Oct 31, 2025 | |
| ELAN Elanco Animal Health | Upgrades: Overweight | $18 → $24 | $22.22 | +8.01% | 4 | Oct 7, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $12 → $14 | $12.84 | +9.03% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $950 → $800 | $785.17 | +1.89% | 8 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $185 → $175 | $174.82 | +0.10% | 4 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $39.39 | +6.63% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $331.49 | -18.55% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $24.88 | +36.66% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $105.04 | +19.00% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $12.02 | +16.47% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $1.32 | +733.33% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.32 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $54.28 | +43.70% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $0.57 | +166,566.67% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.64 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $25.74 | +94.25% | 3 | Nov 2, 2018 |
Teva Pharmaceutical Industries
Dec 16, 2025
Maintains: Overweight
Price Target: $28 → $35
Current: $31.54
Upside: +10.97%
Perrigo Company
Dec 15, 2025
Maintains: Neutral
Price Target: $20 → $18
Current: $13.68
Upside: +31.58%
Eli Lilly and Company
Nov 18, 2025
Maintains: Overweight
Price Target: $1,050 → $1,150
Current: $1,071.64
Upside: +7.31%
Organon & Co.
Nov 11, 2025
Maintains: Underweight
Price Target: $14 → $12
Current: $7.09
Upside: +69.25%
Zoetis
Nov 5, 2025
Maintains: Overweight
Price Target: $230 → $200
Current: $123.54
Upside: +61.89%
IDEXX Laboratories
Nov 4, 2025
Maintains: Overweight
Price Target: $675 → $775
Current: $682.31
Upside: +13.58%
AbbVie
Nov 3, 2025
Maintains: Overweight
Price Target: $250 → $260
Current: $228.79
Upside: +13.64%
Gilead Sciences
Oct 31, 2025
Maintains: Overweight
Price Target: $145 → $150
Current: $125.19
Upside: +19.82%
Elanco Animal Health
Oct 7, 2025
Upgrades: Overweight
Price Target: $18 → $24
Current: $22.22
Upside: +8.01%
Amneal Pharmaceuticals
Sep 16, 2025
Maintains: Overweight
Price Target: $12 → $14
Current: $12.84
Upside: +9.03%
Jun 9, 2025
Maintains: Overweight
Price Target: $950 → $800
Current: $785.17
Upside: +1.89%
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $174.82
Upside: +0.10%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $39.39
Upside: +6.63%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $331.49
Upside: -18.55%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $24.88
Upside: +36.66%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $105.04
Upside: +19.00%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $12.02
Upside: +16.47%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $1.32
Upside: +733.33%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $7.32
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $54.28
Upside: +43.70%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $0.57
Upside: +166,566.67%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $1.64
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $25.74
Upside: +94.25%